首页> 外文期刊>Journal of epidemiology and global health. >First and second line drug resistance among treatment naive pulmonary tuberculosis patients in a district under Revised National Tuberculosis Control Programme (RNTCP) in New Delhi
【24h】

First and second line drug resistance among treatment naive pulmonary tuberculosis patients in a district under Revised National Tuberculosis Control Programme (RNTCP) in New Delhi

机译:在新德里修订的国家结核病控制规划(RNTCP)下的一个地区中的未接受治疗的肺结核患者中的一线和二线耐药

获取原文
       

摘要

There is limited information of level of drug resistance to first-line and second line anti-tuberculosis agents in treatment naive pulmonary tuberculosis (PTB) patients from the Indian region. Therefore, the present prospective study was conducted to determine the antimicrobial susceptibility to first-line and second line anti-TB drug resistance in such patients. Sputum samples from consecutive treatment naive PTB cases registered in Lala Ram Sarup (LRS) district, under RNTCP containing 12 Directly Observed Treatment Centre's (DOTS), were enrolled using cluster sampling technology. A total of 453 samples were received from July 2011 to June 2012. All samples were cultured on solid medium followed by drug susceptibility to first and second line anti-tubercular drugs as per RNTCP guidelines. Primary multi-drug resistance (MDR) was found to be 18/453; (4.0%). Extensively drug resistance (XDR) was found in one strain (0.2%), which was found to be resistant to other antibiotics. Data of drug resistant tuberculosis among treatment naive TB patients are lacking in India. The presence of XDR-TB and high MDR-TB in small population studied, calls for conducting systematic multi-centric surveillance across the country.
机译:在印度地区的初治肺结核(PTB)患者中,对一线和二线抗结核药的耐药水平信息有限。因此,本前瞻性研究旨在确定此类患者对一线和二线抗结核药物耐药性的敏感性。使用整群抽样技术,收集了在Lala Ram Sarup(LRS)地区注册的,连续进行过首次治疗的PTB病例的痰液样本,该样本在RNTCP下包含12个直接观察的治疗中心(DOTS)。从2011年7月至2012年6月共收到453个样品。所有样品均在固体培养基上培养,然后按照RNTCP指南对一线和二线抗结核药物进行药物敏感性分析。发现原发多药耐药性(MDR)为18/453; (4.0%)。在一种菌株(0.2%)中发现了广泛的耐药性(XDR),该菌株对其他抗生素具有耐药性。在印度,缺乏治疗纯正结核病患者的耐药结核病数据。在少数人群中,广泛耐药结核和高耐药结核的存在要求在全国范围内进行系统的多中心监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号